Acta haematologica · 2025
Approach to Hairy-Cell Leukemia in the New Therapeutic Era with Special Emphasis on Age and Comorbidities.
СтатьяОбзорНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Levy Yurkovski Ilana, Tadmor Tamar
Аннотация
BACKGROUND: Hairy-cell leukemia (HCL) is a rare chronic hematologic malignancy, generally presenting with pancytopenia, relative lymphocytosis, monocytopenia, and splenomegaly. Diagnosis is based on typical bone marrow evaluation with the BRAF-V600E mutation being present in almost 100% of cases of classical HCL.
SUMMARY: Treatment usually involves the use of purine analogs (PAs) as first-line therapy. Novel targeting therapies have recently been included in the treatment of therapy-naive HCL such as PA combination with anti-CD20, BRAF inhibitors alone, or combined with anti-CD20. In relapse/refractory disease, other novel agents were studied as BRAF and MEK inhibitors, Bruton tyrosine kinase, or BCL2 inhibitors: all showed encouraging results. Most clinical trials and guidelines do not specify what the optimal approach is for patients with HCL in special situations as elderly population above 80 years old, very young patients below 40 years old, pregnant women, and when leukemia is presented with other comorbidities as active infection or vasculitis.
KEY MESSAGES: In this current manuscript, we summarized our approach to HCL in the era of novel agents with special emphasis on age and comorbidities.
SUMMARY: Treatment usually involves the use of purine analogs (PAs) as first-line therapy. Novel targeting therapies have recently been included in the treatment of therapy-naive HCL such as PA combination with anti-CD20, BRAF inhibitors alone, or combined with anti-CD20. In relapse/refractory disease, other novel agents were studied as BRAF and MEK inhibitors, Bruton tyrosine kinase, or BCL2 inhibitors: all showed encouraging results. Most clinical trials and guidelines do not specify what the optimal approach is for patients with HCL in special situations as elderly population above 80 years old, very young patients below 40 years old, pregnant women, and when leukemia is presented with other comorbidities as active infection or vasculitis.
KEY MESSAGES: In this current manuscript, we summarized our approach to HCL in the era of novel agents with special emphasis on age and comorbidities.